UT Dallas acquires new microCT-enhanced deep-tissue optical imaging system

June 19, 2019
The Department of Bioengineering at the UT Dallas is adding a MILabs Hybrid OI/CT system to its innovative medical imaging solutions. By fusing bioluminescent and fluorescent imaging with ultra-high-resolution CT, this new in-vivo imaging system enables functional treatment imaging of diseases throughout the wholebody of a small animal while providing at the same time critical tissue characterization information.

According to Prof. Kenneth Hoyt, Director of the Small Animal Imaging Core facility: “The combination of 3D optical imaging with ultra-high-resolution microCT expands applications beyond traditional optical imaging. For instance, this Hybrid OI/CT system enables to pinpoint cancer deep into tissue and at the same time, can provide distinctive microvascular characteristics such as blood supply to determine whether tumors are prone to growth and metastasis. This provides prognostic value when monitoring early tumor response to neoadjuvant treatment.”

Prof. Frederik Beekman, CEO/CSO of MILabs adds:” We are excited that Prof. Hoyt’s team, a trend-setter in the disease and treatment effects of microvascular dysfunction, has selected Hybrid 3D OI/CT for his innovative research work. We hope to further collaborate with UT Dallas on future translational research by expanding his system with nuclear imaging capabilities such as PET and SPECT”


About the Department of Biomedical engineering at UT Dallas:
The Department of Bioengineering at UT Dallas integrates biomedical engineering with medicine and biology. Its research is focused on innovate medical solutions that will reduce health care costs, improve human health and increase the quality of life for all humankind. More info at: https://be.utdallas.edu/bioengineering/about/


About MILabs B.V.
This Dutch company has a history of providing innovations to expand the applications of in-vivo imaging using PET, SPECT, Optical and X-ray CT. Available in any combination or as stand-alone systems, MILabs preclinical imaging modalities are globally recognized for being able to deliver the highest quality small-animal
molecular, functional and anatomical images. For more information, visit: www.milabs.com or contact MILabs at info@milabs.com